Multigene Panels in Prostate Cancer Risk Assessment
Home > Medicine > Medicine: general issues > Medical equipment & techniques > Telemedicine > Multigene Panels in Prostate Cancer Risk Assessment
Multigene Panels in Prostate Cancer Risk Assessment

Multigene Panels in Prostate Cancer Risk Assessment


     0     
5
4
3
2
1



International Edition


About the Book

Prostate cancer is the fifth most common malignancy in the world, with a large variation in incidence rates. In 2010, it was estimated that almost a quarter of a million new cases were diagnosed in North America, and more than 36,000 men died from the disease. Apart from age, ethnic group, and family history, the risk factors associated with prostate cancer are unclear, making primary prevention difficult. Striking differences in incidence have been observed for different ethnic groups and populations. A high incidence has been observed in populations of African descent in several countries. First-degree relatives of men with prostate cancer have a two- to threefold increased risk for developing the disease, and its estimated heritability is high. Some patterns of familial aggregation have been observed that are consistent with an autosomal dominant mode of inheritance of a susceptibility gene, but this accounts for no more than 15 percent of cases. Prostate cancer is currently considered to be a complex, multifactorial disease with the vast majority of familial clustering attributed to the interaction of multiple shared moderate to low penetrance susceptibility genes and shared environmental factors within these families. Many epidemiological studies have suggested a wide range of other risk factors for prostate cancer, but these have not been confirmed in controlled trials. The natural history of prostate cancer is highly variable. In a large proportion of men, the disease is indolent, and it is difficult to predict which tumors will be aggressive. African-American men have a poorer prognosis than other groups, independent of comorbidity or access to health services. The value of aggressive management for localized prostate cancer is also debated, and only a small proportion of men with early stage prostate cancer die from the disease within 10 to 15 years of diagnosis. Prostate-specific antigen (PSA) was approved by the U.S. Food and Drug Administration in 1986 for monitoring progression in patients with prostate cancer, and later approved for the detection of the disease in symptomatic men (but not for screening asymptomatic men). A meta-analysis of seven randomized controlled trials of screening using PSA testing alone, or in combination with digital rectal examination, suggested no evidence of benefit in reducing mortality, and some evidence of harms from overdiagnosis. Amidst substantial debate, the argument has been made for developing more accurate screening tests, including possible genetic markers. Single nucleotide polymorphisms (SNPs) are minute inherited variations in the DNA sequence. SNPs occur about once in every 800 base pairs and are the most common type of genetic variation in humans. Since 2001, there have been about 1,000 published studies reporting associations between prostate cancer, SNPs, and other genetic variants. To date, genome-wide association (GWA) studies have identified replicated associations between prostate cancer and almost 40 specific SNPs. The aim of this review is to assess the evidence on the possible value of SNP panels in the detection of and prediction of risk for prostate cancer, and their value in predicting disease prognosis in affected men. This report addresses the evidence on the validity and utility of using SNP panels in the detection, diagnosis, and clinical management of prostate cancer. The specific Key Questions are: 1. What is the analytic validity of currently available SNP-based panels designed for prostate cancer risk assessment? 2. What is the clinical validity of currently available SNP-based panels designed for prostate cancer risk assessment? 3. What is the clinical utility of currently available SNP-based panels for prostate cancer risk assessment, in terms of the process of care, health outcomes, harms, and economic considerations?


Best Sellers



Product Details
  • ISBN-13: 9781483935232
  • Publisher: Createspace Independent Publishing Platform
  • Publisher Imprint: Createspace Independent Publishing Platform
  • Height: 280 mm
  • No of Pages: 170
  • Series Title: English
  • Sub Title: Evidence Report/Technology Assessment Number 209
  • Width: 216 mm
  • ISBN-10: 148393523X
  • Publisher Date: 22 Mar 2013
  • Binding: Paperback
  • Language: English
  • Returnable: N
  • Spine Width: 9 mm
  • Weight: 458 gr


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Multigene Panels in Prostate Cancer Risk Assessment
Createspace Independent Publishing Platform -
Multigene Panels in Prostate Cancer Risk Assessment
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Multigene Panels in Prostate Cancer Risk Assessment

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    New Arrivals



    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!